Virus inactivation by protein denaturants used in affinity chromatography

Biologicals

Volumn 35, Issue 4, 2007, Pages 343-347

  Roberts, Peter L ^a   Lloyd, David ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Affinity chromatography; Gel recycling; Protein denaturants; Virus inactivation

Indexed keywords

ALCOHOL; BIOLOGICAL PRODUCT; GUANIDINE DERIVATIVE; GUANIDINE THIOCYANATE; PROTEIN; SODIUM HYDROXIDE; THIOCYANATE SODIUM; THIOCYANIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UREA;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG SAFETY; ELUTION; GEL CHROMATOGRAPHY; HERPES SIMPLEX VIRUS 1; NONHUMAN; PH; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; SINDBIS VIRUS; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS INFECTIVITY;

CHROMATOGRAPHY, AFFINITY; DRUG CONTAMINATION; ETHANOL; GUANIDINE; GUANIDINES; HERPESVIRUS 1, HUMAN; HUMANS; HYDROGEN-ION CONCENTRATION; POLIOVIRUS; PROTEIN DENATURATION; SINDBIS VIRUS; SODIUM HYDROXIDE; THIOCYANATES; UREA; VACCINIA VIRUS; VIRUS INACTIVATION;

HERPES;

EID: 35248888115     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2007.02.005     Document Type: Article

References (15)

1. In: Brown F., and Lubiniecki A. (Eds). Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev Biologicals 88 (1995)
2. Brorson K., Norling L., Hamilton E., Lute S., Lee K., Curtis S., et al. Current and future approaches to ensure the viral safety of biopharmaceuticals. Dev Biol Basel 118 (2004) 17-29
3. Roberts PL. Virus safety of cell-derived biological products; In: Davis J, Stacey G., editors. Medicines from animal cell culture. Chichester: John Wiley; 2007, in press.
4. International Conference on Harmonisation. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Q5A (RI); 1999.
5. Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency: Note for guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95; 1996.
6. Roberts P. Virus safety of plasma products. Rev Med Virol 6 (1996) 25-38
7. GE Healthcare. Use of sodium hydroxide for cleaning and sanitising chromatography media and systems. Application note 18-1124-57 AE; 2006.
8. Yan Z., and Huang J. Cleaning procedure for protein G affinity columns. J Immunol Methods 237 (2000) 203-205
9. Bill E., Lutz V., Karlsson B.M., Sparrman M., and Allgaler H. Optimisation of protein G chromatography for biopharmaceutical monoclonal antibodies. J Mol Recognit 8 (1995) 90-94
10. Brorson K., Brown J., Hamilton E., and Stein K.E. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chromatogr A 989 (2003) 155-163
11. Hahn R., Shimahara K., Steindl F., and Jungbauer A. Comparison of protein A affinity sorbants III. Life time study. J Chromatogr A 1102 (2006) 224-231
12. Hale G., Drumm A., Harrison P., and Phillips J. Repeated cleaning of protein A affinity column with sodium hydroxide. J Immunol Methods 171 (1994) 15-21
13. GE Healthcare (formally Amersham Biosciences). MabSelect SuRe. Alkali-stabilised protein. A derived medium for capture of monoclonal antibodies. Application note 11-0011-65AA; 2004.
14. Fassina G., Ruvo M., Palombo G., Verdoliva A., and Marino M. Novel ligands for the affinity chromatographic purification of antibodies. J Biochem Biophys Methods 49 (2001) 481-490
15. Kabir S. Immunoglobulin purification by affinity chromatography using protein A mimetric ligands prepared by combinatorial chemical synthesis. Immunol Invest 31 (2002) 263-278